drugset / Trial / NCT06196203
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Timeline
- Start
- 2024-02-07
- Primary completion
- 2026-01
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK117 | Monoclonal antibody | — | Intravenous |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |